scholarly journals Upgrade system device in use of new oral anticoagulants vs. antiplatelet agents

2017 ◽  
Vol 16 ◽  
pp. 10-11
Author(s):  
Márcio Galindo Kiuchi ◽  
Shaojie Chen
Keyword(s):  
Oral Anticoagulants ◽  
Antiplatelet Agents ◽  
New Oral Anticoagulants

Treatment and secondary prevention of venous thromboembolism in cancer patients

2012 ◽  
Vol 03 (03) ◽  
pp. 121-125
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
New Oral Anticoagulants ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

New Oral Anticoagulants and Their Reversal

2015 ◽  
Vol 10 (3) ◽  
pp. 208-216 ◽  
Author(s):  
Ian Pinto ◽  
Anshu Giri ◽  
Umbreen Arshad ◽  
Ajeet Gajra
Keyword(s):  
Oral Anticoagulants ◽  
New Oral Anticoagulants

scholarly journals Postoperative Thromboprophylaxis With New Oral Anticoagulants is Superior to LMWH in Hip Arthroplasty Surgery

2019 ◽  
Vol 477 (6) ◽  
pp. 1335-1343 ◽  
Author(s):  
Piotr Kasina ◽  
Alexander Wall ◽  
Lasse J. Lapidus ◽  
Ola Rolfson ◽  
Johan Kärrholm ◽  
...  
Keyword(s):  
Hip Arthroplasty ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Arthroplasty Surgery

New oral anticoagulants and risks in ENT

2013 ◽  
Vol 38 (4) ◽  
pp. 355-357
Author(s):  
S. Hollis
Keyword(s):  
Oral Anticoagulants ◽  
New Oral Anticoagulants

scholarly journals Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Lisa M. Baumann Kreuziger ◽  
Joseph C. Keenan ◽  
Colleen T. Morton ◽  
David J. Dries
Keyword(s):  
Recombinant Factor Viia ◽  
Factor Viia ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Coagulation Cascade ◽  
Clotting Factors ◽  
Prothrombin Complex Concentrates ◽  
Clotting System ◽  
Clinical Trial Evidence

Ease of dosing and simplicity of monitoring make new oral anticoagulants an attractive therapy in a growing range of clinical conditions. However, newer oral anticoagulants interact with the coagulation cascade in different ways than traditional warfarin therapy. Replacement of clotting factors will not reverse the effects of dabigatran, rivaroxaban, or apixaban. Currently, antidotes for these drugs are not widely available. Fortunately, withholding the anticoagulant and dialysis are freqnently effective treatments, particularly with rivaroxaban and dabigatran. Emergent bleeding, however, requires utilization of Prothrombin Complex Concentrates (PCCs). PCCs, in addition to recombinant factor VIIa, are used to activate the clotting system to reverse the effects of the new oral anticoagulants. In cases of refractory or emergent bleeding, the recommended factor concentrate in our protocols differs between the new oral anticoagulants. In patients taking dabigatran, we administer an activated PCC (aPCC) [FELBA] due to reported benefit in human in vitro studies. Based on human clinical trial evidence, the 4-factor PCC (Kcentra) is suggested for patients with refractory rivaroxaban- or apixaban-associated hemorrhage. If bleeding continues, recombinant factor VIIa may be employed. With all of these new procoagulant agents, the risk of thrombosis associated with administration of factor concentrates must be weighed against the relative risk of hemorrhage.

New oral anticoagulants in patients with atrial fibrillation

The Lancet ◽  
2014 ◽  
Vol 384 (9937) ◽  
pp. 24
Author(s):  
Wim Opstelten ◽  
Maureen van den Donk ◽  
Ton Kuijpers ◽  
Jako S Burgers
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants
Sign in / Sign up

Export Citation Format

Share Document